Henan Taifeng Medical Technology Group Co. LTD
wei sha
vice presidentkangyuan biomedical tech
chunchao jia
department leaderMira Life Science Ventures
Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.
In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.
Mr. Mel Rothberg
ChairmanMSQ Ventures
Mr. Estigarribia Marc
MDShanghai Henlius Biotech
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,